30 Day Trial

Royal Biologics Launches MAGNUS DMSO-Free Viable Cellular Bone Allograft

Share:

Royal Biologics launched MAGNUS, a viable cellular bone allograft. MAGNUS employs viable spine-derived cells collected from a donor's vertebral body that are preserved with a next-generation DMSO-free cryoprotectant.

Industry standard DMSO penetrates and dehydrates the cell from within to prevent crystal formation. At room temperature, DMSO-based cryoprotectants raise concerns about cytotoxicity and negative effects on cell differentiation.

In a recently-published peer-reviewed study of 75 consecutive cases at one-year follow-up, minimally invasive transforaminal lumbar interbody fusion with MAGNUS Viable Allograft demonstrated a 96% fusion rate of the 75 patients with a total of 85 levels achieving fusion at 12 months.

Royal Biologics MAGNUS Allografts - ORTHOWORLD
MAGNUS Viable Cellular Bone Allograft